Browse studies
Find your next paid study
4 recruiting studies matching your filters
Phase 1
A Phase 1/2 Dose Evaluation Trial of the Safety and Preliminary Efficacy of Anti CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleuce…
Warm Autoimmune Hemolytic Anemia (WAIHA)ITP - Immune ThrombocytopeniaWarm Autoimmune Hemolytic Anemia+1 more
Estimated
~$10 – $8,750
CRISPR Therapeutics AGNCT07549698
Congenital Hemolytic and Dyserythropoietic Anemias
The main reason for this research study is to further understand how some red blood cells are formed incorrectly or they have an abnormal metabolism in a way t…
Hemolytic Anemia
Estimated
~$10 – $675
Children's Hospital Medical Center, CincinnatiNCT07649213
Phase 1
A Phase 1 Study to Evaluate the Safety and Tolerability of Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
Background: Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cells to carry oxygen. Research has shown t…
Sickle Cell Disease, Hemolytic Anemia
Estimated
~$10 – $5,625
National Heart, Lung, and Blood Institute (NHLBI)NCT07566494
Phase 2
A Phase 2, Multicenter, Open-Label Study of Zolacabtagene Autoleucel (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Chronic Immune Thrombocytopenia (cITP) and Autoimmune Hemolytic Anemia (AIHA)
The purpose of this study is to evaluate the safety and efficacy of Zola-cel (BMS-986353), in participants with chronic immune thrombocytopenia (cITP) and auto…
Chronic Immune ThrombocytopeniaAutoimmune Hemolytic Anemia
Estimated
~$10 – $8,750
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT07603557